Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of ...

Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

We recently published a list of 12 Most Shorted Stocks in 2025. In this article, we are going to take a look at where CRISPR ...

Akebia Therapeutics commenced an underwritten public offering. The biopharmaceutical company didn't say how many shares of its common stock it expects to sell, nor did it disclose anticipated proceeds ...

Shares of Akebia Therapeutics fell after the company said it has commenced an underwritten public offering. The stock sank 21% to $2.24 in after-hours trading Wednesday. Shares ended the regular ...

Perspective Therapeutics (NYSE:CATX – Get Free Report) will likely be posting its quarterly earnings results after the market ...

Cell therapy biotech bit.bio is slimming its workforce by 25% as the company pivots to focus on biomedical tools instead of ...

TG Therapeutics' strong cash position and Briumvi success fuel growth potential. Find out why TGTX stock is rated a strong ...

Capricor presented preclinical data at the 2024 American Association of Extracellular Vesicles (AAEV) Annual Meeting. The ...

"This year has been an extremely successful year for LENZ, and we have continued to make progress in the fourth quarter and ...

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...